125 related articles for article (PubMed ID: 1287877)
1. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit.
Carrie D; Caranobe C; Gabaig AM; Larroche M; Boneu B
Thromb Haemost; 1992 Dec; 68(6):637-41. PubMed ID: 1287877
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic activity of dermatan sulphates, heparins and their combination in an animal model of arterial thrombosis.
Iacoviello L; D'Adamo MC; Pawlak K; Polishchuck R; Wollny T; Buczko W; Donati MB
Thromb Haemost; 1996 Dec; 76(6):1102-7. PubMed ID: 8972038
[TBL] [Abstract][Full Text] [Related]
3. Antithrombotic and bleeding effects of a new synthetic direct thrombin inhibitor and of standard heparin in the rabbit.
Cadroy Y; Caranobe C; Bernat A; Maffrand JP; Sié P; Boneu B
Thromb Haemost; 1987 Aug; 58(2):764-7. PubMed ID: 3672429
[TBL] [Abstract][Full Text] [Related]
4. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate.
Dol F; Petitou M; Lormeau JC; Choay J; Caranobe C; Sie P; Saivin S; Houin G; Boneu B
J Lab Clin Med; 1990 Jan; 115(1):43-51. PubMed ID: 2299256
[TBL] [Abstract][Full Text] [Related]
6. The venous antithrombotic profile of naroparcil in the rabbit.
Millet J; Theveniaux J; Brown NL
Thromb Haemost; 1994 Dec; 72(6):874-9. PubMed ID: 7740457
[TBL] [Abstract][Full Text] [Related]
7. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological actions of sulodexide.
Ofosu FA
Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
[TBL] [Abstract][Full Text] [Related]
9. Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does not.
Cadroy Y; Dol F; Caranobe C; Petitou M; Lormeau JC; Sié P; Choay J; Boneu B
Thromb Haemost; 1988 Apr; 59(2):295-8. PubMed ID: 2838927
[TBL] [Abstract][Full Text] [Related]
10. [Dermatan sulfate and the prevention of experimental venous thrombosis].
Desnoyers P; Bara L; Samama M
Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis.
Jackson CV; Crowe VG; Frank JD; Wilson HC; Coffman WJ; Utterback BG; Jakubowski JA; Smith GF
J Pharmacol Exp Ther; 1992 May; 261(2):546-52. PubMed ID: 1578372
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis--evidence for an anticoagulant-independent mechanism.
Barbanti M; Calanni F; Milani MR; Marchi E; Semeraro N; Colucci M
Thromb Haemost; 1993 Feb; 69(2):147-51. PubMed ID: 8456427
[TBL] [Abstract][Full Text] [Related]
13. The haemorrhagic and antithrombotic effects of dermatan sulphate.
Fernandez F; Van Ryn J; Ofosu FA; Hirsh J; Buchanan MR
Br J Haematol; 1986 Oct; 64(2):309-17. PubMed ID: 3778825
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
[TBL] [Abstract][Full Text] [Related]
15. Clinical experience with a new antithrombotic (dermatan sulfate) in chronic hemodialysis patients.
Nurmohamed MT; Knipscheer HC; Stevens P; Krediet RT; Roggekamp MC; Berckmans RJ; ten Cate JW
Clin Nephrol; 1993 Mar; 39(3):166-71. PubMed ID: 8462205
[TBL] [Abstract][Full Text] [Related]
16. Prevention and therapy of experimental venous thrombosis in rabbits by desmin 370.
Colucci M; Rossiello MR; Barbanti M; Calanni F; Semeraro N
Thromb Haemost; 1998 Aug; 80(2):338-41. PubMed ID: 9716163
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure.
Ryan KE; Lane DA; Flynn A; Ireland H; Boisclair M; Shepperd J; Curtis JR
Thromb Haemost; 1992 Nov; 68(5):563-9. PubMed ID: 1455403
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic activity in vivo of SDZ 217-766, a low-molecular weight thrombin inhibitor in comparison to heparin.
Tapparelli C; Metternich R; Gfeller P; Gafner B; Powling M
Thromb Haemost; 1995 Apr; 73(4):641-7. PubMed ID: 7495072
[TBL] [Abstract][Full Text] [Related]
19. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Kaiser B; Fareed J
Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
[TBL] [Abstract][Full Text] [Related]
20. Low affinity heparin is an antithrombotic agent.
Gray E; Cesmeli S; Lormeau JC; Davies AB; Lane DA
Thromb Haemost; 1994 Feb; 71(2):203-7. PubMed ID: 8191399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
